| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a2b35000c1dac8ca70cf9fd035ab2e65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c7c9a5f129bbc0596101c30a7e228252 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18143
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18134
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-585
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-53
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5256
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18132
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18121 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Y204-01087
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1051
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-93 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-768
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-01 |
| filingDate |
2015-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_42e66bf0dd9bc5b68678a6aca8244e9a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4a97abbaec9aa925628b152bb002e3e3 |
| publicationDate |
2016-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2016101326-A1 |
| titleOfInvention |
Oncolytic heterologous recombination newcastle disease virus,preparation method and application thereof |
| abstract |
Provided are an oncolytic heterologous recombination Newcastle disease virus (NDV), preparation method and application thereof. The heterologous recombination NDV can express an alpha (1, 3) galactosyltransferase (alpha (1, 3) GT); the alpha (1, 3) GT is the protein represented by the following B1) or B2): B1) the protein has an amino acid sequence of SEQ ID No.1; and B2) the protein is derived from B1) and has a function of the alpha (1, 3) GT obtained by substituting and/or deleting and/or adding one or more amino acid residue(s) in the amino acid sequence represented by SEQ ID No.1. The recombination NDV can be used for the tumor treatment. |
| priorityDate |
2014-12-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |